Characteristics of patient samples used for bone marrow aromatase expression experiments
| UPN . | Age, y . | Sex . | IMiD dosing, mg/d . | Dex dosing, mg/wk . | Platelet count, × 109/L . | n of Megs per 50 LPFs . |
|---|---|---|---|---|---|---|
| 25 | 58 | F | NA | NA | 286 | 29 |
| 26 | 51 | M | NA | NA | 249 | 34 |
| 27 | 64 | M | NA | NA | 167 | 14 |
| 28 | 56 | M | NA | NA | 309 | 18 |
| 29 | 65 | M | NA | NA | 174 | 19 |
| 30 | 54 | F | Pom 3 | 40 | 96 | 18 |
| 31 | 58 | M | Len 10 | NA | 90 | 24 |
| 32 | 59 | M | Len 10 | NA | 54 | 22 |
| 33 | 62 | F | Len 10 | NA | 95 | 11 |
| 34 | 64 | M | Len 25 | 40 | 52 | 15 |
| UPN . | Age, y . | Sex . | IMiD dosing, mg/d . | Dex dosing, mg/wk . | Platelet count, × 109/L . | n of Megs per 50 LPFs . |
|---|---|---|---|---|---|---|
| 25 | 58 | F | NA | NA | 286 | 29 |
| 26 | 51 | M | NA | NA | 249 | 34 |
| 27 | 64 | M | NA | NA | 167 | 14 |
| 28 | 56 | M | NA | NA | 309 | 18 |
| 29 | 65 | M | NA | NA | 174 | 19 |
| 30 | 54 | F | Pom 3 | 40 | 96 | 18 |
| 31 | 58 | M | Len 10 | NA | 90 | 24 |
| 32 | 59 | M | Len 10 | NA | 54 | 22 |
| 33 | 62 | F | Len 10 | NA | 95 | 11 |
| 34 | 64 | M | Len 25 | 40 | 52 | 15 |
Dex, dexamethasone; Len, lenalidomide; LPF, low-power field; Meg, megakaryocyte; NA, not applicable; Pom, pomalidomide; UPN, unique patient number.